CUMULATIVE INDEX 1995

Volume 24

March	ENDOCRINE DISORDERS IN PREGNANCY, pages 1–212
June	ENDOCRINE ASPECTS OF AGING, pages 213–458
September	CLINICAL DISORDERS OF FLUID AND ELECTROLYTE METABOLISM, pages 459–662
December	THYROID CANCER I, pages 663–904

Note: Page numbers of article titles are in **boldface** type.

Abortion, spontaneous, in chronic thyroiditis, 60
  in diabetic pregnancies, 83–84
Absorptiometry, in bone density/mass measurement, 335–337
ACE inhibitors, in elderly diabetic patients, 267–268
  hyperkalemia and, 581
Acid-base balance, in potassium homeostasis, 575, 577
Acidosis, potassium homeostasis and, 575, 577, 581
Acromegaly, bone effects, 388–389
  in pregnancy, 5
ACTH. See *Adrenocorticotropic hormone.*
Addison's disease, bone density in, 384
  hyperkalemia from, 580
  in pregnancy, 141–142
Adenomas, aldosterone-producing, 595, 601–608
  pituitary, in pregnancy, 3–6
  of thyroid, paraganglioma-like, 727–728
Adenomatosis polyposis coli gene, 877
ADFR therapy for osteoporosis, 357
Adrenal disorders of pregnancy, **139–151**
  Addison's disease, 141–142
  adrenal cortical changes in normal pregnancy, 139–141
  Cushing's syndrome, 142–144
  pheochromocytoma, 144–146
  steroid medication complications, 146–148
Adrenal gland, in bone disease, 382–384
Adrenal hyperplasia, primary, 604–605, 608
Adrenal imaging, in primary aldosteronism, 602, 603–604
Adrenal insufficiency, primary
  hyperkalemia from, 580
Adrenal vein sampling, in primary aldosteronism, 602, 604
Adrenocorticotropic hormone (ACTH), aging and, 219–220
  in glucocorticoid-remediable aldosteronism, 596, 608
  in pregnancy, 2, 142
Aerobic exercise, in diabetic pregnancies, 120–124
Age, at diagnosis of papillary thyroid carcinoma, 733–734
  thyroid nodules and, 664, 669–670
AGES scoring for papillary thyroid carcinoma, 739
Aging. See also *Elderly.*
  diabetes mellitus and, **255–272**
  drug-induced metabolic disease and, **395–420**
  endocrine causes of bone disease and, **373–393**
  male reproductive system and, **297–315**
  menopause and female reproductive system and, **273–295**
  osteoporosis and, **317–371**
  Paget's disease and, **421–450**
Alagille syndrome, 714
Albuterol, in potassium homeostasis, 587
Alcohol, in dietary treatment of hypertension, 650–651
  osteoporosis from, 330, 408
Aldosterone, aging and, 247
  excretion rate, in primary aldosteronism, 600
  natriuretic peptides and, 501, 502

Aldosterone *(Continued)*
in nephrotic syndrome, 471
normal function, 511–513
in potassium homeostasis, 575, 577
Aldosterone-producing adenomas, 595
idiopathic hyperaldosteronism versus, 601–604
renin-responsive, 604–605, 608
treatment, 606–608
Aldosteronism. See *Primary aldosteronism; Secondary aldosteronism.*
Algodystrophy, 29
Alkaline phosphatase, in Paget's disease, 448–449
Alkalosis, potassium homeostasis and, 575, 577
Alpha-adrenergic stimulation, in potassium homeostasis, 578, 582
Alzheimer's disease, vasopressin in, 240–244
Amenorrhea, prolonged, 386–387
AMES classification for papillary thyroid carcinoma, 739
Amiloride, hyperkalemia and, 581
in primary aldosteronism, 607, 609
Amphetamines, in orthostatic edema, 543–546
Anabolic steroids, in hypogonadism, 386
in osteoporosis treatment, 347, 355–356, 386
Anaplastic carcinoma, radioiodine therapy and, 830
Androgens, deficiency in elderly men, 302–303
menopausal changes, 282–283
Aneurysms, ovarian artery, 165
Angiotensin-converting enzyme inhibitors, in elderly diabetic patients, 267–268
hyperkalemia and, 581
Angiotensin I-III, in aldosterone function, 511–512
ANH, aging and, 245–246
ANP. See *Atrial natriuretic peptide.*
Anticonvulsants, bone disorders from, 325, 331, 410–411
APC gene, in follicular thyroid cancer, 877
Apparent mineralocorticoid excess, **613–621**
Arginine hydrochloride, hyperkalemia and, 583
Arginine vasopressin. See *Vasopressin.*
Arrhythmias, in magnesium deficiency, 628
Arterial circulation, in body homeostasis, 460, 462–463
peripheral arterial vasodilation, in cirrhosis, 465–466
in pregnancy, 469
Arteriosclerosis, male impotence from, 308–309
Arthritis, in Paget's disease, 448
in pregnancy, 148, 196–197
rheumatoid, 196–197, 326
Ascites formation, overflow theory, 464
Astatine 211, 791
Asthma, corticosteroids and, in pregnancy, 147
Atherosclerosis, in elderly diabetic patients, 267
magnesium deficiency and, 632
Atrial natriuretic peptide (ANP), actions, 498–502
aging and, 245–246
in cardiac failure, 468
gene, 485, 486
in nephrotic syndrome, 472
receptors, 489–490
regulation and metabolism, 491–497
sodium balance and, in pregnancy, 521
structure, 483, 484
tissue distribution and gene expression, 487–488
Auriculin cardiodilatin. See *Atrial natriuretic peptide.*
Autoantibody interference in serum thyroglobulin measurement, 847–851
Autoimmune disorders in pregnancy, corticosteroids and, 147–148
HIV and associated infections, 201–202
leprosy, 201
malaria, 201
multiple sclerosis, 197
myasthenia gravis, 200
rheumatoid arthritis, 196–197
systemic lupus erythematosus, 198–199
thyroid disorders, 59–60, 199
Autoimmune responses, maternal, cytokine patterns of fetoplacental unit and, 194–196
Autoimmune thyroid disease. See *Graves' disease; Hashimoto's thyroiditis.*
Autonomous thyroid nodules, 672, 694
Avascular necrosis, glucocorticoid therapy and, 383
AVP. See *Vasopressin.*

BEL dosimetry, 811
Beta-adrenergic stimulation, in potassium homeostasis, 577–578, 582
Beta-blockers, in pregnancy, in Graves' disease, 51–52
in pheochromocytoma, 146
Betamethasone, in pregnancy, complications, 147
Bilateral hyperthecosis, in pregnancy, 164
Biphosphonates. See *Diphosphonates.*
Bladder cancer, from radioiodine therapy, 830

Blood pressure regulation, dietary factors and, **643–655**
BNP. See *Brain natriuretic peptide.*
Body composition changes with age, 221–225
Body fluid homeostasis, arterial circulation integration in, 462–463
  mechanisms, 460–462
Bone density measurement, 334–335
  indications, 337–339
  techniques, 335–337
Bone disease, drug-induced metabolic, **395–420**
    anticonvulsants, 410–411
    glucocorticoids, 396–404
    heparin, 407–408
    other agents, 408–409
    thyroxine, 404–407
  endocrine causes, **373–393**
    adrenal gland, 382–384
    growth hormone, 387–389
    hypogonadism, 384–387
    parathyroid gland, 375–382
    thyroid gland, 374–375
Bone fragility, ultrasound transmission velocity and, 339
Bone loss. See also *Osteoporosis.*
  age-related, 320–321
  postmenopausal, 321
  from systemic disease, 322–327
Bone marrow suppression, from radioiodine therapy, 828
Bone mass, measurement, 334–335
    indications, 337–339
    techniques, 335–337
  peak, calcium and, 344
    osteoporosis and, 320
Bone metabolism, magnesium deficiency and, 629–631
Bone metastases from thyroid cancer, radioiodine therapy and, 814–815
Bone mineral density, thyroid hormone suppressive therapy effects on, 689–691
Bone remodeling, 395
Bone scans, in Paget's disease, 448
  in thyroid cancer, 831–832
Bone status in pregnancy and lactation, 26–28
Bone turnover, in pregnancy, 18
Bowel diversion and resection, secondary aldosteronism in, 523–524
Brain metastases in thyroid cancer, 824–825
Brain natriuretic peptide (BNP), actions, 499–502
  gene, 485, 487
  receptors, 489–490
  regulation and metabolism, 492–497
  structure, 483, 484
  tissue distribution and gene expression, 488
Breast-feeding, Graves' disease and, 52
  insulin and diet for, 95–96
Bromocriptine, in orthostatic edema, 546
  for pituitary adenomas, in pregnancy, 4, 5

Caffeine, osteoporosis from, 330, 408
Calcitonin, in osteoporosis, 227
    prevention, 341, 343–344
    treatment, 347, 353–354, 402–403
  for Paget's disease, 429–431
  thyroid nodules and, 674
Calcitriol, in osteoporosis, prevention, 341, 345–346
    treatment, 347, 355
  in pregnancy, 17
  secondary hyperparathyroidism and, 379–380
Calcium. See also *Hypercalcemia; Hypocalcemia.*
  in dietary treatment of hypertension, 647–648
  hypercalcemia in magnesium deficiency, 628, 629–630
  in osteoporosis, 329
    deficiency as risk factor, 329, 345–346
    glucocorticoid-induced, 400, 401–402
    prevention, 341, 344–345
    treatment, 347, 354–355
  secondary hyperparathyroidism and, 379
Calcium channel blockers, in primary aldosteronism, 608, 609
Calcium disorders of pregnancy, **15–39**
  bone status, 26–28
  calcium metabolism in hypertension and preeclampsia, 32–33
  changes in maternal calcium-parathyroid axis, 15–16
    bone turnover, 18
    calcium, 16–17
    parathyroid hormone, 17–18
    possible role of parathyroid hormone–related protein, 18–21
    vitamin D, 17
  hypercalcemia, familial benign (hypocalciuric), 24
    hyperparathyroidism, 21–23
    induced by parathyroid hormone–related protein, 23–24
    thyroid disease and, 24
  hypocalcemia, in fetus of diabetic mother, 93
    hypomagnesemia, 26
    hypoparathyroidism, 24–25
    pseudohypoparathyroidism, 25–26

Calcium disorders of pregnancy *(Continued)*
vitamin D deficiency, 26
nephrolithiasis, 33
osteoporosis, 26, 28
heparin-induced, 31–32
of hip, idiopathic transient, 29
lactation-associated, 30–31
spinal, postpregnancy, 29–30
Calcium salts, intravenous, in potassium homeostasis, 587
Calories, for elderly diabetic patients, 256–257
restriction, in diabetic pregnancies, 114–116
Captopril, hyperkalemia and, 581
in orthostatic edema, 546
in renovascular hypertension, 514
Captopril test, in primary aldosteronism, 599–600
Carbohydrate, in dietary treatment of hypertension, 649–650
for elderly diabetic patients, 257
Cardiac failure, renal sodium excretion in, 467–468
Cardiac function, thyroid hormone suppressive therapy effects on, 688–689
Cardionatrin. See *Atrial natriuretic peptide.*
Cardiovascular complications of Paget's disease, 425–426
Cardiovascular conditioning, in diabetic pregnancies, 120–124
Carney's complex, 714–715
CD4+ T cells, in immunologic response, 188–192
Cell-mediated immune responses, cytokines and, 188–191
Cellular necrosis, hyperkalemia and, 582–583
Central diabetes insipidus. See *Neurohypophyseal diabetes insipidus.*
Central nervous system disease, bone loss from, 327
Cerebrospinal fluid, vasopressin in, 235
in Alzheimer's disease, 242
Cervix, relaxin effects on, 179
Chemical agents, papillary thyroid carcinoma and, 717–718
Chlorpropamide, in diabetes insipidus, 567–569
for elderly diabetic patients, 260, 261
Cholesterol, chemical structure and relationships, 277
in elderly diabetic patients, 267
Chromium, in elderly diabetic patients, 257
Chronic obstructive pulmonary disease, growth hormone treatment, 226
Chronic renal failure, secondary aldosteronism and, 521–523
Cigarette smoking, osteoporosis from, 330, 409
vasopressin and, 238, 239
Circulation, arterial, in body homeostasis, 460, 462–463
peripheral arterial vasodilation, in cirrhosis, 465–466
in pregnancy, 469
atrial natriuretic peptide effects on, 500
Cirrhosis, renal sodium excretion in, 463–466
Clear cell variant of papillary thyroid carcinoma, 726–727
Climacteric period, 274–275
CNP. See *C-type natriuretic peptide.*
Columnar cell variant of papillary thyroid carcinoma, 725
Computed tomography, in primary aldosteronism, 602, 603
quantitative, in bone density/mass measurement, 337
Congenital malformations. See also *Fetal complications.*
in diabetic pregnancies, 84–88
in Graves' disease, 52–53
Congestive heart failure, renal sodium excretion in, 467–468
Connective tissue disorders, bone loss from, 326–327
COPD, growth hormone treatment, 226
Corpus luteum in pregnancy, 162–163, 175–177
Corticosteroids. See *Steroids.*
Cortisol, diabetogenesis in pregnancy, 77
in maternal plasma, 140–141
in pregnancy-related disorders, 141–144
Counseling, prepregnancy, in diabetes, 94
Cowden's syndrome, 715
Cranial diabetes insipidus. See *Neurohypophyseal diabetes insipidus.*
Creatinine, in diabetic nephropathy, in pregnancy, 79
C-type natriuretic peptide (CNP), actions, 499, 502
gene, 485, 487
receptors, 489–490
regulation and metabolism, 492, 493–497
structure, 483–485
tissue distribution and gene expression, 488
Cushing's disease, osteoporosis in, 383
Cushing's syndrome, in pregnancy, 5–6, 142–144
Cyclins and cylin inhibitors, in follicular thyroid cancer, 878
Cyclosporine, hyperkalemia and, 581
hypertension from, secondary aldosteronism in, 524–525
Cysts, ovarian, in pregnancy, corpus luteum cyst, 162–163

hyperreactio luteinalis, 157–161
large solitary luteinized follicular cyst, 161–162
thyroid, 693–694
Cytokines, in follicular thyroid cancer, 792–793
immunologic response and, in pregnancy, 187–196

DDAVP. See also *Vasopressin.*
in Alzheimer's disease, 243–244
in diabetes insipidus, 565, 567–569
Decidua, relaxin effects on, 179–180
Deflazacort, in glucocorticoid-induced osteoporosis, 404
Deformities in Paget's disease, 422–423
Dermatomyositis, in pregnancy, corticosteroids and, 148
DEXA, in bone density/mass measurement, 336–337
Dexamethasone, in apparent mineralocorticoid excess, 618
in pregnancy, complications, 147
Dextroamphetamine, in orthostatic edema, 544, 545
Diabetes insipidus, **549–572**
classification, 550
definition, 549
differential diagnosis, 564–567
etiology, 550–551
pathogenesis, gestational diabetes, 555
nephrogenic diabetes, 553–554
neurohypophyseal diabetes, 551–553
primary polydipsia, 554–555
pathophysiology, gestational diabetes, 564
nephrogenic diabetes, 559–560
neurohypophyseal diabetes, 555–559
primary polydipsia, 560–564
in pregnancy, 8
symptoms and signs, 549–550
treatment, gestational diabetes, 569–570
nephrogenic diabetes, 569
neurohypophyseal diabetes, 567–569
primary polydipsia, 569
Diabetes mellitus, in elderly, **255–272**
bone loss from, 324–325
complications, acute, 265–267
chronic, 267–269
hypoglycemia, 264–265
presentation and epidemiology, 255–256
therapy, combination, 264
diet, 256–258
exercise, 258–259
goals, 256
insulin, 261–264
oral hypoglycemic agents, 259–261
insulin-dependent vs. non–insulin-dependent, 74–75
magnesium deficiency in, 626–627, 633–634
in pregnancy. See *Gestational diabetes; Pregestational diabetes.*
Diabetic hyperosmolar coma, 265–267
Diabetic ketoacidosis, 265
Diabetic nephropathy, 267
Diabetic nephropathy and hypertension, in pregnancy, 78–79
Diabetic neuropathy, in elderly, 268
Diabetic retinopathy, in elderly, 268
in pregnancy, 76–78
Diet, in diabetic pregnancies, 114–116
for elderly diabetic patients, 256–258
for nursing mothers, 95
papillary thyroid carcinoma and, 717
Dietary treatment of hypertension, **643–655**
dietary ions, 644–648
macronutrients and dietary regimens, 648–652
Diffuse sclerosing variant of papillary thyroid carcinoma, 725–726
Digitalis, hyperkalemia and, 582
1,25-Dihydroxyvitamin D. See *Calcitriol; Vitamin D.*
Dilantin, bone effects, 410–411
Diphosphonates, in osteoporosis, glucocorticoid-induced, 403
prevention, 341
treatment, 347, 351–353, 403
for Paget's disease, 426–429, 431
Dipsogenic diabetes insipidus, 551
pathogenesis, 552
pathophysiology, 562–564
Disuse osteoporosis, 327–328
Diuretics, hyperkalemia and, 581
in orthostatic edema, 542–543
osteoporosis from, 331
Drug therapy. See *Medications.*
Dual-energy x-ray absorptiometry, in bone density/mass measurement, 336–337
Dual-photon absorptiometry, in bone density/mass measurement, 336

Eclampsia, endothelium and, 470
Ectopic deciduosis, 163–164
Edema, idiopathic, **531–547**
clinical features, 538–540
diagnosis, 540–542
pathophysiology, 532–538
treatment, 542–546
massive ovarian, 165–166
renal sodium excretion and, **459–479**
afferent and efferent mechanisms, 460–462
arterial circulation integrity in body homeostasis, 462–463

Edema *(Continued)*
in cardiac failure, 467–468
in cirrhosis, 463–466
in nephrotic syndrome, 470–473
in pregnancy, 468–470
Effective blood volume, 459
Elderly. See also *Aging.*
anterior pituitary function and growth hormone use in, **213–231**
diabetes mellitus in, **255–272**
hormonal aspects of fluid and sodium balance in, **233–253**
osteoporosis in, **317–371**
Electrolyte metabolic disorders. See *Fluid and electrolyte metabolic disorders.*
Embryogenesis, parathyroid hormone–related protein in, 20–21
Enalapril, hyperkalemia and, 581
Encapsulated papillary thyroid carcinoma, 722
Endocrine system and aging, 213–214
Endocrinopathies, bone loss from, 322–325
Endometrial carcinoma, estrogen replacement and, 288, 289, 342
Endometrium, relaxin effects on, 179–180
Endothelin, in cardiac failure, 467
Endothelium, in pregnancy, 469–470
Environmental agents, papillary thyroid carcinoma and, 717–718
EORTC prognostic scoring system for papillary thyroid carcinoma, 738–739
Ephedrine, in orthostatic edema, 543
Erythremia, fetal, in diabetes, 93
Estradiol, diabetogenesis in pregnancy, 77
Estrogen(s). See also *Hormone replacement therapy.*
deficiency, 283
follicular thyroid cancer and, 762, 764
menopausal changes, 282–283
in postmenopausal bone loss, 321
osteoporosis prevention, 340–343
osteoporosis treatment, 347, 351
in pregnancy, 80–81
secretion through female life span, 280–281
smoking and, in osteoporosis, 409
synthesis, 276
Ethanol, osteoporosis from, 330, 408
vasopressin secretion and, 237
Etidronate, in osteoporosis, glucocorticoid-induced, 403
prevention, 341
treatment, 347, 351–353
for Paget's disease, 427–428
European Organization for Research on Treatment of Cancer, prognostic scoring system for papillary thyroid carcinoma, 738–739
Exercise, in diabetic pregnancies, 120–124
for elderly diabetic patients, 258–259
osteoporosis and, 329–330
Extenal beam radiotherapy, radiosensitizing and other drugs with, in follicular thyroid cancer, 790–791

Familial benign hypercalcemia, 24
Familial polyposis, 714, 877
Fat, dietary, elderly diabetic patients and, 257
hypertension and, 649
Female reproductive system. See *Menopause and aging female reproductive system.*
Fertility, male, 308–310
radioiodine therapy and, 826–828
Fetal complications. See also *Congenital malformations.*
in diabetes, 106–108
hyperbilirubinemia and erythremia, 93
hypocalcemia, 93
hypoglycemia, 90, 92
macrosomia, 89–90, 106–108
respiratory distress, 92
in Graves' disease, 52–54
Fetoplacental unit, cytokine patterns of, maternal autoimmune responses and, 194–196
Fetus, adrenal gland, 139–140
growth and differentiation, parathyroid hormone–related protein in, 20–21
thyroid function, 44–45
Fine-needle aspiration biopsy, in follicular thyroid cancer, 775–776
of thyroid nodules, adjuncts, 680
distribution of results, 677
impact on clinical practice, 676–677
in pregnancy, 61–62
reliability, 679
specimen adequacy, 677–678
suspicious results, 678–679
Fluid and electrolyte metabolic disorders, apparent mineralocorticoid excess, **613–621**
diabetes insipidus, **549–572**
dietary factors and blood pressure regulation, **643–655**
idiopathic edema, **531–547**
magnesium, **623–641**
natriuretic hormones, **481–509**
potassium homeostasis and hyperkalemic syndromes, **573–591**
primary aldosteronism, **593–612**
renal sodium excretion and edematous disorders, **459–479**
secondary aldosteronism, **511–529**
Fluid and sodium balance in elderly, **233–253**
Fluid deprivation test, in diabetes insipidus, 565

Fluid homeostasis, arterial circulation in, 462–463
  mechanisms, 460–462
Fluoride, in osteoporosis treatment, 347, 348–351
Follicle stimulating hormone, in female reproductive system, 279, 280
  menopausal changes, 281–282
  in pregnancy, 1, 2
  radioiodine therapy and, 826–827
Follicular cyst of pregnancy and puerperium, large solitary luteinized, 161–162
Follicular thyroid cancer, **761–801**
  clinical presentation and diagnosis, 773–776
  demographics and epidemiology, 761–765
  etiology and pathogenesis, 772–773
  experimental therapy and future outlook, 790
    cytokines and immunotherapy, 792–793
    hormones other than thyroid hormone, 791–792
    increasing biologic effect of radiotherapy, 790–791
    radioiodine substitutes, 791
  follow-up, 787–790
  genetics. See *Genetics, of follicular thyroid cancer.*
  pathology and classification, 765–772
  prognosis, 782–787
  treatment, adjuvant therapy, 779–780
    primary tumor, 776–778
    recurrent and metastatic disease, 780–782
Follicular variant of papillary thyroid carcinoma, 722–723
Fractures, in osteoporosis, 333–334
    estrogen replacement and, 340–342
    fluoride and, 349
    glucocorticoid therapy and, 382, 383
  in Paget's disease, 423–424, 445–446
Fructosamine, in gestational diabetes diagnosis, 112–113
FSH. See *Follicle stimulating hormone.*
Furosemide, in orthostatic edema, 542, 544

Gardner's syndrome, 714
Gastrointestinal disorders, bone loss from, 325–326
Gastrointestinal symptoms from radioiodine therapy, 825–826
Gastroparesis, in elderly diabetic patients, 268
Gender, papillary thyroid carcinoma and, 734–735
  thyroid nodules and, 664–666, 670
Genetics, of follicular thyroid cancer, **865–883**
  cyclins and cylin inhibitors, 878
  early events, 867–868
  epidemiologic and genetic considerations, 866–867
  gene therapy, 792
  growth factors, 867–868, 869, 870
  metastatic behavior, 878–879
  miscellaneous oncogenes, 872
  molecular evolution, 772–773
  perspective, 879
  predisposing factors, 764
  ras genes, 868, 870
  tumor suppressor genes, 872–873
    APC, 877
    mdm2 (a p53-binding protein), 877
    p53, 874–877
    Rb, 873–874
  tyrosine kinase oncogenes in papillary carcinoma, 870–872
  of natriuretic peptides, 485–488
  of papillary thyroid carcinoma, 714–716, 866–867
  tyrosine kinase oncogenes, 870–872
Genetic testing for glucocorticoid-remediable aldosteronism, 605–606
Geriatrics. See *Aging; Elderly.*
Gestational diabetes, **103–138**
  definition and historical perspective, 103–106
  long-term implications, infant outcome, 129
  maternal outcome. 125–128
  maternal and fetal risks, 106–108
  medical management, 113–114
    diet, 114–116
    exercise, 120–124
    insulin, 116–120
  obstetric management, 124–125
  prevalence, 108
  relaxin and, 178, 181
  screening and diagnosis, 109–113
Gestational diabetes insipidus, differential diagnosis, 564–567
  pathogenesis, 555
  pathophysiology, 564
  treatment, 569–570
Gestational hypertension, hypothyroidism and, 55–56
GH. See *Growth hormone.*
Glipizide, 259, 260, 261
Glucocorticoid-remediable aldosteronism, 596
  adrenal steroidogenesis in, 597
  genetic testing for, 605–606
  treatment, 608–609
Glucose. See also *Hyperglycemia; Hypoglycemia.*

Glucose *(Continued)*
homeostasis, magnesium deficiency and, 631–634
level in elderly diabetic patients, 256, 259, 266
management in pregnancy, 94–95, 114–124
Glucose testing, in gestational diabetes diagnosis, fasting plasma glucose assay, 111–112, 113
glucose challenge test, 109
glycosylated proteins, 112–113
oral glucose tolerance test, 104, 105, 110, 111
self-monitoring, 83, 110–111
Glyburide, for elderly diabetic patients, 260, 261
Glycosylated hemoglobin, in diabetes, in pregnancy, 81–82, 112
GnRH, in female reproductive system, 278–279
postmenopausal changes, 281
Goiter, in pregnancy, 61
neonatal goiter from antithyroid drugs, 53
Gonadotropin, human chorionic. See *Human chorionic gonadotropin.*
Gonadotropin-releasing hormone (GnRH), in female reproductive system, 278–279
postmenopausal changes, 281
Granulosa cell proliferations, 164
Graves' disease, papillary thyroid carcinoma and, 735–736
in pregnancy, breast-feeding and, 52
diagnosis, 48–49
infants born to mothers with, 52–54
maternal and neonatal complications, 52
natural history, 48
postpartum, 65–66
treatment of hyperthyroidism, 49–52
thyroid cancer risk and, 672
Growth factors, in follicular thyroid cancer, 867–868, 869, 870
Growth hormone (GH), aging and, 215–217
in bone disease, 387–389
deficiency in elderly, 220
in pregnancy, 2
in diabetic retinopathy, 77
secretion regulation, 214
use of hGH in elderly, 220, 222–228

Hashimoto's thyroiditis, papillary thyroid carcinoma and, 735
in pregnancy, 58, 199
thyroid cancer risk and, 671–672
hCG. See *Human chorionic gonadotropin.*
Head and neck irradiation, thyroid nodules and, 666–667, 670, 695
Hearing loss, in Paget's disease, 424
Heart failure, renal sodium excretion in, 467–468
Hemochromatosis, hypogonadism from, 385
Hemoglobin, glycosylated, in diabetes, in pregnancy, 81–82, 112
Heparin, hyperkalemia and, 580–581
osteoporosis from, 407–408
in pregnancy, 31–32
hGH. See *Human growth hormone.*
Hilus cell hyperplasia, in pregnancy, 164
Hip, transient osteoporosis, in pregnancy, 28, 29
HIV, in pregnancy, 201–202
Homeostasis, body fluid, arterial circulation in, 462–463
mechanisms, 460–462
Hook effects in thyroglobulin assays, 846–847
Hormone replacement therapy, benefits, 285
duration, 289–290
indications and contraindications, estrogen, 287–288
progesterone, 288–289
in osteoporosis, 340–343, 351
preparations and effects, 285–286
recommendations, 287
Hormones and aging, 213–214
Hot flashes/flushes, 284
hPTH, in osteoporosis treatment, 347, 356–357
11β-HSD, 615–619
Human chorionic gonadotropin (hCG), in pregnancy, in luteoma of pregnancy, 151, 156
relaxin and, 175–176
as thyroid stimulator, 2, 48
Human chorionic somatomammotropin, in pregnancy, 81
diabetogenesis, 77
Human growth hormone (hGH), use in elderly, 220
for anabolic effects, 225–227
body composition and, 222–225
complications, 227–228
Human immunodeficiency virus, in pregnancy, 201–202
Human parathyroid peptide, in osteoporosis treatment, 347, 356–357
Humoral immune responses, cytokines and, 188–191
Hürthle cell carcinomas, 771
variant of papillary thyroid carcinoma, 726
Hyalinizing trabecular adenoma, 727–728

18-Hydroxy-corticosterone, in primary aldosteronism, 601–603
Hydroxyproline, in Paget's disease, 449
11β-Hydroxysteroid dehydrogenase, 615–619
Hyperaldosteronism, idiopathic, 595
  aldosterone-producing adenoma versus, 601–604
  treatment, 607–608
Hyperbilirubinemia, fetal, in diabetes, 93
Hypercalcemia, in magnesium deficiency, 628, 629–620
  in pregnancy and lactation, 21–24
Hyperemesis gravidarum, transient hyperthyroidism of, 46–48
Hyperglycemia, consequences in pregnancy, congenital malformations, 84–88
    macrosomia, 89–90
    spontaneous abortion, 83–84
    stillbirth, 88–89
  diabetic retinopathy and, 76–77
Hyperkalemia, etiology, 578–579
    diminished potassium excretion, 579–581
    excess exogenous potassium load, 583–584
    intracellular to extracellular potassium shifts, 581–583
    pseudohyperkalemia, 584
  evaluation, 584–585
  manifestations, 585
  treatment, 585–587
Hyperkalemic periodic paralysis, 583
Hyperkalemic syndromes, potassium homeostasis and, **573–591**
Hyperlipidemia, in elderly diabetic patients, 267
Hypernatremia, in elderly, 247
Hyperosmolar coma, diabetic, 265–267
Hyperparathyroidism, osteitis fibrosa cystica, 377–378
  in pregnancy, 21–23
  secondary, 378–380
Hyperparathyroid osteopenia, 325, 375–377
Hyperphosphatemia, secondary hyperparathyroidism and, 379
Hypertension, apparent mineralocorticoid excess and, 618–619
  dietary treatment, **643–655**
    dietary ions, 644–648
    macronutrients and dietary regimens, 648–652
  hypokalemia and, diagnostic approach, 598
  magnesium deficiency and, 627, 633
  in pregnancy, calcium metabolism in, 32–33
    in diabetes, 78–79
    hypothyroidism and, 55–56
  primary aldosteronism and, 594
  secondary aldosteronism and, 513–525
Hyperthecosis, bilateral, 164
Hyperthyroidism, bone loss from, 323–324, 404
  in pregnancy, 46
    causes, 46
    Graves' disease, 48–52
      infants born to mothers with, 52–54
    hyperemesis gravidarum, 46–48
    postpartum, 64–66
  subclinical, bone mineral density and, 689–690
    cardiac function and, 688–689
  thyroid nodules and, 673
Hypocalcemia, fetal, in diabetes, 93
  in magnesium deficiency, 628, 629–630
  in pregnancy and lactation, 24–26
Hypocalciuric hypercalcemia, in pregnancy, 24
Hypoglycemia, in elderly diabetic patients, 256, 264–265
  fetal, in diabetes, 90, 92
  vasopressin and, 238
Hypogonadism, bone loss from, 322, 323
  in men, 384–386
  in women, 386–387
Hypokalemia, hypertension and, diagnostic approach, 598
  in magnesium deficiency, 628
  in primary aldosteronism screening, 597
Hypomagnesemia, 624, 626–627, 635. See also *Magnesium deficiency.*
  in pregnancy, 26
Hyponatremia, 247–248
Hypoparathyroidism, bone density increase in, 380
  in pregnancy, hypocalcemia and, 24–25
  from radioiodine therapy, 829
Hypopituitarism in adults, 220
Hyporeninemic hypoaldosteronism, 247, 580
Hyporreactio luteinalis, 157
  clinical presentation, 157
  differential diagnosis, 158, 160
  management, 161
  origin, 160
  ovarian hyperstimulation syndrome, 160
  pathologic features, 157–158, 159
Hypothalamic-testicular axis, aging and, pituitary/hypothalamic function, 303–306
    sex steroid changes, 300–303
  normal physiology, 299–300
Hypothalamus, vasopressin and, 234
Hypothalamus-pituitary-thyroid axis function, in pregnancy, 41–43
Hypothyroidism, follicular thyroid cancer and, 774
  in pregnancy, 54–57

Hypothyroidism *(Continued)*
neonatal hypothyroidism from antithyroid drugs, 53
postpartum, 64–66

Idiopathic edema. See *Edema, idiopathic.*
Idiopathic hyperaldosteronism, 595, 601–604, 607–608
IGF-I. See *Insulin-like growth factor–I.*
Imaging, adrenal, in primary aldosteronism, 602, 603–604
in Paget's disease, 440–445, 448
in thyroid cancer, 831–833
follicular, 774–775
of thyroid nodules, 674–676
Immune deviation, 189
Immunologic response in pregnancy, **187–205**
altered cytokine production by splenocytes and decidual lymphocytes, 192–194
autoimmune disorders, 196–202
cell-mediated and humoral immune responses, 188–191
cytokine patterns of fetoplacental unit affecting maternal autoimmune responses, 194–196
Immunotherapy, in follicular thyroid cancer, 792–793
Impotence, 308–309
Infectious diseases, in pregnancy, 201–202
Infertility, radioiodine therapy and, 826–828
Insular carcinomas, 771–772
Insulin, magnesium deficiency and, 631–633
in potassium homeostasis, 577, 582, 586–587
Insulin-like growth factor–I (IGF-I), aging and, 215–216
in bone disease, 387–389
human growth hormone therapy and, 222–228
secretion regulation, 214
Insulin therapy, in diabetic pregnancies, 116–120
for elderly diabetic patients, 261–264
for nursing mothers, 95–96
Interferon-gamma, immunologic response and, 188–195
Interleukins, in follicular thyroid cancer, 792
immunologic response and, in pregnancy, 187–196
Intestinal diversion and resection, secondary aldosteronism in, 523–524
Intrauterine fetal death, in diabetic pregnancies, 88–89
Iodine, dietary, radioiodine therapy and, 819
Iodine therapy, radioactive. See *Radioiodine therapy.*
Ionizing radiation, thyroid cancer and, 716–717
Irradiation, thyroid cancer and, 716
thyroid nodules and, 666–667, 670, 695
Ischemic hypertensive conditions, secondary aldosteronism in, 513–525

Kayexalate, in hyperkalemia, 586
Ketoacidosis, diabetic, 265
Kidney, in edematous states, 459. See also *Sodium, renal excretion.*
Kyphosis, 333

Labor onset, parathyroid hormone–related protein and, 19
Lactation, bone status in, 26–28
changes in maternal calcium-parathyroid axis in response to, 15–21
hypercalcemia in, 21–24
hypocalcemia in, 24–26
osteoporosis and, 28, 30–31
Lactogen, placental, corpus luteum and, 177
Leprosy, in pregnancy, 201
Leukemia, radioiodine therapy and, 829–830
Levothyroxine, bone disease from, 374–375, 404–407
for follicular thyroid cancer, 779, 781–782
in hypothyroidism, 56, 58–59
for papillary thyroid carcinoma, 745–746
Leydig cells, aging and, 301, 304
LH. See *Luteinizing hormone.*
LHRH, in male aging, 305–306
testosterone and, 299
Lipids, in elderly diabetic patients, 267
Lithium, in diabetes insipidus, 553
with radiotherapy, 790
Lobectomy (and isthmusectomy) for thyroid cancer, 682, 741, 777, 804
Long bones, imaging in Paget's disease, 440
Lower extremity pain, fluoride and, 350
Lupus erythematosus, systemic, in pregnancy, 198–199
corticosteroids and, 147–148
Luteinizing hormone (LH), in aging male, 303–306
in female reproductive system, 279, 280
in hypogonadism, 385
menopausal changes, 281–282

in pregnancy, 1, 2
Luteinizing hormone-releasing hormone (LHRH), in male aging, 305–306
testosterone and, 299
Luteoma of pregnancy, 153
clinical presentation, 154
differential diagnosis, 156
hyporreactio luteinalis vs., 160
management, 157
origin, 156
pathologic features, 154–155
Lymphocytes, activated, in murine pregnancy, 192–194
Lymphocytic hypophysitis, in pregnancy, 6

MACIS scoring for papillary thyroid carcinoma, 739–740
Macrosomia, in diabetic pregnancies, 89–90, 106–108
Magnesium, in dietary treatment of hypertension, 648
metabolic disorders, **623–641**
metabolism, 623–624
Magnesium deficiency, 624
bone and mineral metabolism and, 629–631
causes, 624–627
in diabetes mellitus, 626–627
diagnosis, 634–635
manifestations, 627–628
in pregnancyhypocalcemia and, 26
treatment, 635–636
vascular function and glucose homeostasis and, 631–634
Magnesium tolerance test, 634–635
Magnetic resonance imaging, in diabetes insipidus, 567
in primary aldosteronism, 603
Malaria, in pregnancy, 201
Male reproductive system. See *Reproductive system, male aging.*
Malignant hypertension, secondary aldosteronism and, 517–518
Malnutrition, growth hormone treatment, 225–226
Mammary gland, relaxin effects on, 180
mdm2, in follicular thyroid cancer, 877
Medications, male impotence from, 308, 309
metabolic bone disease from, **395–420**
anticonvulsants, 410–411
glucocorticoids, 396–404
heparin, 407–408
other agents, 408–409
thyroxine, 404–407
for osteoporosis, prevention, 340–346
treatment, 346–357
osteoporosis from, 330
vasopressin release and, 244
Medroxyprogesterone, side effects, 288–289
Men, reproductive system of. See *Reproductive system, male aging.*
Menopause and aging female reproductive system, **273–295**
climacteric period, 274–275
estrogen deficiency, 283
hormone replacement therapy, 285–290
hot flashes/flushes, 284
hypogonadism, 386–387
neuroendocrine changes, 281–283
ovaries, 275–276
premature menopause, 387
sex steroids, 276–277
urogenital atrophy, 284–285
Menstrual cycle, hormonal integration of, 279–280
osteoporosis and, 332
MEN 2, 145, 673, 715
Metabolic bone disease, drug-induced, **395–420**
Metabolic disorders, fluid and electrolyte. See *Fluid and electrolyte metabolic disorders.*
Metabolism of natriuretic peptides, 496–497
Metastases from thyroid cancer, brain, 824–825
follicular thyroid cancer, 780–782
genetics, 878–879
papillary carcinoma, 731–733, 742, 746
radioiodine therapy and, 812–815
Methimazole, in Graves' disease, in pregnancy, 50–51, 53
Metoclopramide, vasopressin secretion and, 237–238, 239
Mineral metabolism, magnesium deficiency and, 629–631
Mineralocorticoid receptors, 614–615
Mineralocorticoids, excess, apparent, **613–621**
primary aldosteronism, **593–612**
in potassium homeostasis, 577
Miscarriage, in chronic thyroiditis, 60
in diabetic pregnancies, 83–84
Mithramycin, for Paget's disease, 431
Molecular genetics of thyroid tumors, **865–883**
Multiple sclerosis, in pregnancy, 197
Muscle relaxants, hyperkalemia and, 583
Myasthenia gravis, in pregnancy, 200
corticosteroids and, 148
Myometrium, relaxin effects on, 179

National Diabetes Data Group classification system, 104–105

Natriuretic hormones, **481–509**
actions, 497–501
comparative effects, 501–502
integrative, 503
chemistry and biology, genes, 485–487
receptors, 488–491
structure, 483–485
tissue distribution and gene expression, 487–488
regulation and metabolism, 491–497
significance, 503
Nausea and vomiting, from radioiodine therapy, 825–826
Neck pain and tenderness, nonsalivary, from radioiodine therapy, 823
Necrosis, pituitary, in Sheehan's syndrome, 6, 7
Neonatal morbidity, in Graves' disease, 52–53
Neoplastic disease, bone loss from, 327
Nephrogenic diabetes insipidus, differential diagnosis, 564–567
pathogenesis, 553–554
pathophysiology, 559–560
treatment, 569
Nephrolithiasis, in pregnancy, 33
Nephropathy, diabetic, in pregnancy, 78–79
Nephrotic syndrome, renal sodium excretion in, 470–473
Neuroendocrine changes, postmenopausal, 281–283
Neurogenic diabetes insipidus. See *Neurohypophyseal diabetes insipidus.*
Neurohumoral mediators in body homeostasis, 460–462
Neurohypophyseal diabetes insipidus, differential diagnosis, 564–567
pathogenesis, 551–553
pathophysiology, 555–559
treatment, 567–569
Neurohypophyseal system, vasopressin and, 234
Neurologic complications of radioiodine therapy, 824–825
Neurologic disorders, bone loss from, 327
in Paget's disease, 424–425
Neuropathy, diabetic, in elderly, 268
Neutral protamine Hagedorn insulin therapy, for elderly diabetic patients, 262–263
Nifedipine, in primary aldosteronism, 608
Nitric oxide (NO), in cardiac failure, 467
in cirrhosis, 466
in pregnancy, 469–470
Nonsteroidal antiinflammatory drugs, hyperkalemia and, 581
Norepinephrine, in cardiac failure, 467
Norethindrone, in hyperparathyroid osteopenia, 377
side effects, 288–289
NPH insulin therapy, for elderly diabetic patients, 262–263
NSAIDs, hyperkalemia and, 581
Nutrition, bone formation and, 320
bone loss and, 321
in diabetic pregnancies, 114–116
for elderly diabetic patients, 256–258
for nursing mothers, 95

Obstetric management in diabetic pregnancies, 124–125
Octreotide, in follicular thyroid cancer, 791–792
18-OH-B, in primary aldosteronism, 601–603
25-OHD, anticonvulsants and, 410–411
18-OH-F, in primary aldosteronism, 602, 603
Oncogenes, follicular thyroid cancer and, 772, 865–866. See also *Genetics, of follicular thyroid cancer.*
papillary thyroid carcinoma and, 715–716, 870–872
Orthopedic surgery for Paget's disease, 431–432
Orthostatic edema. See *Edema, idiopathic.*
Osteitis fibrosa cystica, 377–378
Osteoarthritis, in Paget's disease, 448
Osteogenesis imperfecta, 326
Osteomalacia, 396
anticonvulsants and, 410–411
parathyroid gland in, 381–382
Osteopenia. See *Bone disease; Bone loss; Osteoporosis.*
Osteoporosis, **317–371.** See also *Bone disease.*
classification, 317–318
clinical features and diagnostic aspects, 328
bone density/mass measurement, 334–339
history taking, 328–332
physical examination, 332–334
ultrasound transmission velocity, 339
in Cushing's disease, 383
disuse, 327–328
hypogonadism and, 384, 385, 386
from medications, glucocorticoids, 322–323, 331, 382–383, 397–404
heparin, 407–408
other drugs, 408–409
thyroxine, 374–375, 404–407
pathophysiology, 319, 395
age-related bone loss, 320–321
bone loss secondary to systemic disease, 322–327
peak bone mass, 320

postmenopausal bone loss, 321
pharmacologic approach to prevention, 340
calcitonin, 343–344
calcium, 344–345
1,25-dihydroxyvitamin D_3 and analogs, 345–346
estrogen, 340–343
in pregnancy, 26, 28
heparin-induced, 31–32
of hip, idiopathic transient, 28, 29
lactation-associated, 28, 30–31
spinal, postpregnancy, 28, 29–30
risk factors, 318–319
treatment, 346–348
anabolic steroids, 355–356
calcitonin, 353–354
calcium, 354–355
coherence therapy, 357
1,25-dihydroxyvitamin D_3, 355
diphosphonates, 351–353
estrogen, 351
growth hormone, 226–227
human parathyroid peptide, 356–357
monotherapy summary, 347
sodium fluoride, 348–351
Osteosarcoma, in Paget's disease, 425, 446–447
Ovarian cycle, hormonal integration of, 279–280
Ovarian disorders of pregnancy, **153–169**
corpus luteum cyst, 162–163
ectopic deciduosis, 163–164
hyperreactio luteinalis, 157–161
large follicular cyst, 161–162
luteoma, 153–157
massive edema, 165–166
ovarian artery aneurysm, 165
Ovaries, aging and, 275–276
function, radioiodine therapy and, 827–828
hyperstimulation, 160, 178
Overflow theory of ascites formation, 464
18-Oxo-F, in primary aldosteronism, 602, 603
Oxyphilic (Hürthle cell) variant of papillary thyroid carcinoma, 726
Oxytocin, relaxin and, 177

PAC/PRA ratio, in primary aldosteronism screening, 599
Paget's disease of bone, **421–450**
arthritis in, 448
bone scans, CT, and MR imaging, 448
clinical features, 421–423
complications, 445–446
cardiovascular, 425–426
fractures, 423–424
neurologic, 424–425
osteosarcomatous transformation, 425
historical perspective, 437
laboratory evaluation, 448–449
pathology, 438–440
radiographic diagnosis, 440–448
long bones, 440
pelvis and other sites, 443–445
skull, 440–441
spine, 443
skeletal distribution, 438
treatment, 426
calcitonin, 429–431
diphosphonates, 426–429, 431
orthopedic surgery, 431–432
plicamycin, 431
tumors and, 425, 446–447
Pain, in Paget's disease, 422
Pamidronate, in glucocorticoid-induced osteoporosis, 403
for Paget's disease, 428–429
Pancreatic disorders of pregnancy. See *Gestational diabetes; Pregestational diabetes.*
Papillary microcarcinoma, 721–722
Papillary thyroid carcinoma, **711–760**
diagnosis, 718–719
etiology, 713
environmental factors, 717–718
familial and ethnic factors, 714
genetic syndromes and oncogenes, 714–716, 870–872
ionizing radiation, 716–717
incidence and prevalence, 712–713
management, levothyroxine therapy, 745–746
progression of disease despite therapy, 746
radioiodine therapy, 743–745
surgery, 740–742
pathology, 719–720
clear cell variant, 726–727
columnar cell variant, 725
diffuse sclerosing variant, 725–726
encapsulated papillary carcinoma, 722
follicular variant, 722–723
histologic subtypes, relative proportions, 721
miscellaneous variants, 728
oxyphilic (Hürthle cell) variant, 726
papillary microcarcinoma, 721–722
tall cell variant, 723–725
trabecular or solid variant, 727–728
prognostic risk factors, 728–729
autoimmune thyroid disease, 735–736
demographic, 733–735
histopathologic, 729–733
scoring schemes, 737–740
thyroid surgery, 736–737
proportion of cases relative to follicular thyroid cancer, 761–762, 763

Papillary thyroid carcinoma *(Continued)*
survival, 784–785
tyrosine kinase oncogenes in, 870–872
vascular invasion and metastases, 731–733, 742, 746
Paraganglioma-like adenomas of thyroid, 727–728
Parathyroid, dysfunction from radioiodine therapy, 829
Parathyroidectomy, in chronic renal failure, 380
for osteopenia, 376–377
Parathyroid gland. See also *Hyperparathyroidism; Hypoparathyroidism.*
in bone disease, 375
hyperparathyroid osteopenia, 375–377
hypoparathyroidism, 380
osteitis fibrosa cystica, 377–378
osteomalacia, 381–382
secondary hyperparathyroidism, 378–380
glucocorticoids and, 400–401
Parathyroid hormone (PTH), in bone disease, 375, 377, 378, 380
magnesium deficiency and, 629–631
in pregnancy, 17–18
deficiency, 24–25
pseudohypoparathyroidism and, 25
Parathyroid hormone–related protein (PTHrP), in pregnancy, 18–19
in embryogenesis, fetal growth, and differentiation, 20–21
hypercalcemia induced by, 23–24
lactation and, 20–21
onset of labor and, 19
placental calcium transport and, 19
Parathyroid peptide, in osteoporosis treatment, 347, 356–357
Paraventricular nucleus, vasopressin and, 234
Parturition, relaxin and, 182
Pedersen hypothesis of maternal hyperglycemia, 90
Pelvic girdle, relaxin effects on, 180–181
Pelvic imaging in Paget's disease, 443–445
Penicillin G, hyperkalemia and, 583
Peripheral arterial vasodilation, in cirrhosis, 465–466
in pregnancy, 469
p53 tumor suppressor gene, follicular thyroid cancer and, 873, 874–877
papillary thyroid carcinoma and, 716
Phenytoin, bone effects, 410–411
Pheochromocytoma, in pregnancy, 144–146
Phosphate, secondary hyperparathyroidism and, 379
Pituitary diabetes insipidus. See *Neurohypophyseal diabetes insipidus.*
Pituitary disorders in pregnancy, **1–14**
anterior, pituitary adenomas, 3–6
pituitary insufficiency, 6–7
posterior, 8
Pituitary gland, aging effects on anterior function, 214–215
adrenocroticotropic hormone, 219–220
growth hormone, 215–217, 220–225
prolactin, 217–218
thyroid-stimulating hormone, 218–219
in aging male, 303–306
anatomic and physiologic changes in pregnancy, 1–2
relaxin effects on, 181
Placental calcium transport, parathyroid hormone–related protein and, 19
Plasma volumes, in nephrotic syndrome, 470–471
PLAT, 727–728
Platybasia, in Paget's disease, 424
Plicamycin, for Paget's disease, 431
Polydipsia. See *Primary polydipsia.*
Polymyositis, in pregnancy, corticosteroids and, 148
Polyposis, familial, 714, 877
Polyuria, in diabetes insipidus, 549
Postmenopausal (type I) osteoporosis, 318, 319
Posture, in orthostatic edema, 532–538
Posture test, in orthostatic edema, 541–542
in primary aldosteronism, 601, 602
Potassium. See also *Hyperkalemia; Hypokalemia.*
aging and, 247
in dietary treatment of hypertension, 646–647
homeostasis, extrarenal, 576–578
hyperkalemic syndromes and, **573–591**
renal, 574–576
in primary aldosteronism screening, 597
renal tubular handling of, 574
in secondary hyperaldosteronism, 511, 512–513, 525
chronic renal failure and, 522–523
Prednisone, osteoporosis from, 397–398. See also *Steroid-induced osteoporosis.*
Preeclampsia, calcium metabolism in, 32–33
endothelium and, 470
Pregestational diabetes, **73–101**
blood glucose self-monitoring, 83
classification, 74–75
fetopathy of infant of diabetic mother, hyperbilirubinemia and erythema, 93
hypocalcemia, 93
hypoglycemia, 90, 92
macrosomia, 89–90
respiratory distress, 92
glycosylated hemoglobin measurement, 81–82

hyperglycemia consequences, congenital malformations, 84–88
macrosomia, 89–90
spontaneous abortion, 83–84
stillbirth, 88–89
management, insulin and diet for nursing mothers, 95–96
labor and delivery, 94–95
prepregnancy counseling and assessment, 94
protocols, 90–92
maternal complications, 74–75
cardiovascular disease, 80
nephropathy and hypertension, 78–79
retinopathy, 76
hyperglycemia and, 76–77
pregnancy as risk factor for, 77–78
normal physiologic stresses of pregnancy and, 80–81
Pregnancy, endocrine disorders in, adrenal, **139–151**
calcium, **15–39**
immunologic response and, **187–205**
ovarian, **153–169**
pancreatic, gestational diabetes, **103–138**
pregestational diabetes, **73–101**
pituitary, **1–14**
relaxin and, **171–186**
thyroid, **41–71**
renal sodium excretion in, 468–470
secondary aldosteronism in, 519–521
Pregnenolone, chemical structure and relationships, 277
Premarin, 286, 287
Primary adrenal hyperplasia, 604–605, 608
Primary adrenal insufficiency, hyperkalemia from, 580
Primary aldosteronism, **593–612**
clinical features, 593–594
diagnosis, 596–601
differential diagnosis, 601–606
etiologies, 594–596
treatment, 606–609
Primary polydipsia, differential diagnosis, 564–567
pathogenesis, 554–555
pathophysiology, 560–564
treatment, 569
Primary reninism, 518
Progesterone, chemical structure and relationships, 277
in female reproductive system, 280
in pregnancy, 81
diabetogenesis, 77
replacement therapy, 288–289
for osteoporosis prevention, 342–343
Prolactin, aging and, 217–218
in pregnancy, 1–2, 81
corpus luteum and, 176–177
diabetogenesis, 77
Prolactinoma, in pregnancy, 3–5
Propranolol, in pregnancy, in Graves' disease, 51–52
in pheochromocytoma, 146
Propylthiouracil (PTU), in Graves' disease, in pregnancy, 50–51, 53
Prostaglandins, in pregnancy, 469
relaxin and, 177
Protein(s), in dietary treatment of hypertension, 648–649
for elderly diabetic patients, 257
glycosylated, in diabetes, 112–113
Pseudohyperparathyroidism, in pregnancy, hypocalcemia and, 25–26
Pseudohypoaldosteronism, hyperkalemia from, 580
Psychogenic diabetes insipidus, 551
pathogenesis, 554–555
pathophysiology, 560–562
PTH. See *Parathyroid hormone.*
PTHrP. See *Parathyroid hormone–related protein.*
pTNM classification of papillary thyroid carcinoma, 737–738
p21, in follicular thyroid cancer, 878
Pulmonary disease, bone loss from, 327
Pulmonary fibrosis, from radioiodine therapy, 830
Pulmonary metastases from thyroid cancer, radioiodine therapy and, 812–813

Race, paillary thyroid carcinoma and, 714
Radiation, ionizing, thyroid cancer and, 716–717
Radiation therapy, thyroid cancer and, 716. See also *Radioiodine therapy, for thyroid cancer.*
thyroid nodules and, 666–667, 670, 695
Radioiodine ablation for thyroid cancer, 804–805
ablative dose, 806–807
choosing ablation, 805–806
who should not be ablated, 807–809
Radioiodine imaging of thyroid cancer, serum thyroglobulin measurement versus, 854–855
Radioiodine therapy, neonatal exposure, 53
for thyroid cancer, **803–839.** See also *Radioiodine ablation for thyroid cancer.*
approaches, 809, 811–812
follicular, 779–780, 781, 790–791
indications, 809
maximizing radioiodine uptake, low-iodine diet, 819
optimal diagnostic scan dose, 819–822

Radioiodine therapy *(Continued)*
other methods, 822–823
thyroid-stimulating hormone stimulation, 816–817, 819
metastatic thyroid carcinoma, bone metastases, 814–815
extrathyroidal lymph node metastases, 812
locally invasive thyroid cancer, 815
pulmonary metastases, 812–813
optimizing capabilities of I–131, 815–816
papillary thyroid carcinoma, 743–745
post-therapy follow-up, diagnostic radioiodine scans and serum thyroglobulin levels, 830–831
other diagnostic studies, 831–833
protocols, 818
radiation considerations, 833–834
side effects, bladder cancer, 830
bone marrow suppression, 828
gastrointestinal symptoms, 825–826
leukemia, 829–830
neurologic complications, 824–825
nonsalivary neck pain and tenderness, 823
ovarian function and female fertility, 827–828
parathyroid dysfunction, 829
pulmonary fibrosis, 830
sialadenitis, 823–824
taste dysfunction, 828
testicular function and male fertility, 826–827
transformation to anaplastic carcinoma, 830
surgery and, 804
Radiology. See *Imaging.*
Radionuclide scans, in Paget's disease, 448
of thyroid nodules, 674–675
ras genes, in follicular thyroid cancer, 868, 870
Rb gene, in follicular thyroid cancer, 873–874
Relaxin and its role in pregnancy, **171–186**
biologic effects in women, 178–179
cervix, 179
endometrium and decidua, 179–180
mammary gland, 180
miscellaneous, 181–182
myometrium, 179
pelvic girdle, 180–181
pituitary gland, 181
uterine quiescence and parturition, 182
historical perspective, 171–172
measurement, bioassays, 173–174
immunoassays, 174–175
secretion, 175–176
control, 176–177
hyperrelaxinemic states, 177–178
hyporelaxinemic states, 177
sources, 172
structure, 172–173
synthesis, 173
Renal disease, bone loss from, 325
Renal failure, chronic, secondary aldosteronism and, 521–523
secondary hyperparathyroidism in, 378–379
Renal sodium excretion. See *Edema, renal sodium excretion and.*
Renal system, in elderly diabetic patients, 267–268
vasopressin and, 239–240
Renin, natriuretic peptides and, 501
in primary aldosteronism screening, 597, 599
Renin-angiotensin-aldosterone axis/system, 511–512
aging and, 246–247
in cardiac failure, 468–469
Renin-angiotensin system, aldosterone function and, 511–512
in nephrotic syndrome, 471
in pregnancy, 519
Reninism, primary, 518
Renin-producing tumors, secondary aldosteronism and, 518–519
Renovascular hypertension, secondary aldosteronism and, 513–517
Reproductive system, female, 278–280
aging. See *Menopause and aging female reproductive system.*
male aging, **297–315**
hypothalamic-testicular axis, 299–306
impotence from medications or arteriosclerosis, 308–309
sexual function in elderly men, 298–299
spermatogenesis, 309–310
testosterone and sexual activity, 306–308
Respiratory distress, fetal, in diabetes, 92
Retinoblastoma (Rb) gene, in follicular thyroid cancer, 873–874
Retinoids, with radiotherapy, 791
Retinopathy, diabetic, in elderly, 268
in pregnancy, 76–78
RET proto-oncogene, papillary thyroid carcinoma and, 715–716, 871–872
Rheumatoid arthritis, bone loss from, 326
in pregnancy, 196–197
corticosteroids and, 148
Rheumatologic complications of diabetes, 269

SAG scoring for papillary thyroid carcinoma, 740

Saline infusion, in primary aldosteronism, 600–601
Salmon calcitonin, in osteoporosis, prevention, 341, 343–344
treatment, 347, 353–354, 402–403
for Paget's disease, 429
Salt, in dietary treatment of hypertension, 644–646
Sarcomatous transformation in Paget's disease, 425, 446–447
Scintigraphy, in primary aldosteronism, 603–604
of thyroid nodules, 674–675
Scoliosis, 333
Secondary aldosteronism, **511–529**
in chronic renal failure, 521–523
iatrogenic, 523–525
in malignant hypertension, 517–518
in pregnancy, 519–521
in renin-producing tumors, 518–519
in renovascular hypertension, 513–517
Seizures, bone loss and fractures and, 325
Senile growth hormone deficiency, 387–388
Senile secondary hyperparathyroidism, 380
Senile (type II) osteoporosis, 318
Sex steroid hormones, female reproduction and, 276, 278
gender and, 275
in male aging, 300–303
menopausal changes, 282–283
structures and relationships, 277
Sexual development, gender and, 275
Sexual function in elderly men, 297, 298–299
Sheehan's syndrome, in pregnancy, 6–7
SIADH, 244, 248
Sialadenitis, from radioiodine therapy, 823–824
Single-photon absorptiometry, in bone density/mass measurement, 335–336
Skull imaging in Paget's disease, 440–441
Smoking, osteoporosis from, 330, 409
vasopressin and, 238, 239
Sodium, in dietary treatment of hypertension, 644–646
hormonal regulation in elderly, 243–247
hypernatremia and hyponatremia, 247–248
in hyperaldosteronism, 512–513
renal excretion, edema and, **459–479**
afferent and efferent mechanisms, 460–462
arterial circulation in body homeostasis, 462–463
in cardiac failure, 467–468
in cirrhosis, 463–466
in nephrotic syndrome, 470–473
orthostatic edema, 533–535, 541–542
in pregnancy, 468–470
Sodium bicarbonate, in hyperkalemia, 586
Sodium fluoride, in osteoporosis treatment, 347, 348–351
Sodium polystyrene sulfonate resin, in hyperkalemia, 586
Solid variant of papillary thyroid carcinoma, 727–728
Somatomedin C. See *Insulin-like growth factor–I.*
Somatostatin, in follicular thyroid cancer, 791
Spermatogenesis, age effects on, 309–310
radioiodine therapy and, 827
Spinal osteoporosis, postpregnancy, 28, 29–30
Spine imaging in Paget's disease, 443
Spironolactone, in primary aldosteronism, 607, 609
Split tolerance, 189
Steroid-induced osteoporosis, 382–383, 396–397
age and gender in, 398–399
annualized bone loss rates, 397–398
distribution, 397
doses, 397
hormone changes in, 401
management, 401–404
pathogenesis/pathophysiology, 323, 331, 382, 399–401
skeletal growth factors and cytokines in, 401
temporal pattern of bone loss, 398
Steroids, anabolic, in hypogonadism, 386
in osteoporosis treatment, 347, 355–356, 386
therapy in pregnancy, complications, 146–148
Stillbirth, in diabetic pregnancies, 88–89
Sulfonylureas, for elderly diabetic patients, 259–261, 264
Sunshine, osteomalacia and, 381
osteoporosis and, 331–332
Suprachiasmatic nucleus, vasopressin and, 234
Supraoptic nucleus, vasopressin and, 234
Sympathetic adrenergic activity, in potassium homeostasis, 577–578, 582
Syndrome of inappropriate antidiuretic hormone secretion, 244, 248
Syndrome X, 264
Systemic lupus erythematosus, in pregnancy, 198–199
corticosteroids and, 147–148

T cells, in immunologic response, 188–192
T-helper cells in autoimmune disorders in pregnancy, 198–202
Tacrolimus, hyperkalemia and, 581
Tall cell variant of papillary thyroid carcinoma, 723–725

Tamoxifen, in follicular thyroid cancer, 791
in glucocorticoid-induced osteoporosis, 404
Tapazole (methimazole), in Graves' disease, 50
Taste dysfunction, from radioiodine therapy, 828
TBG, in pregnancy, 41–43
TeBG, 301
Testicular function, radioiodine therapy and, 826–827
Testosterone, changes with aging, 300–303
pituitary/hypothalamic function, 303–305
in luteoma of pregnancy, 154
male sexual activity and, 306–308
normal physiology, 299–300
osteopenia and, 384
supplementation, 302–303
in hypogonadism, 385–386
Testosterone-binding globulin, 301
Testosterone cypionate, 384–385
Testosterone enanthate, 384–385
Thallium scanning, in thyroid cancer, 832
Th1 and Th2 cytokines, in immunologic response, 187–192
Th cells, in autoimmune disorders, in pregnancy, 198–202
Theophylline, osteoporosis from, 408–409
Thyroglobulin, follicular thyroid cancer and, 774, 788–789
serum levels in radioiodine therapy follow-up, 830–831
thyroid nodules and, 673–674
Thyroglobulin measurement, **841–863**
methodologic problems, 842
assay precision, 844–846
assay sensitivity, 844
autoantibody interference, 847–851
hook effects, 846–847
standardization, 842–844
serum levels in differentiated thyroid carcinoma, 851–852
clinical sensitivity, ^{131}I imaging versus, 853–855
postoperative monitoring, 852–853
preoperative values, 852
use of serum thyroglobulin/TSH relationships to optimize TSH suppression therapy, 856–858
while on versus off thyroid hormone suppression therapy, 855–856
Thyroid cancer, evaluation and management of solid thyroid nodule, **663–710**
follicular, **761–801**
genetics, **865–883**
papillary thyroid carcinoma, **711–760**
in pregnancy, 61–62, 742
radioiodine therapy, **803–839**
thyroglobulin measurement in, **841–863**
Thyroid carcinoma, papillary. See *Papillary thyroid carcinoma.*
Thyroid cysts, 693–694
Thyroid disorders. See also *Hyperthyroidism; Hypothyroidism.*
bone loss from, 323–324
Thyroid disorders of pregnancy, **41–71**
autoimmune disorders, 59–60, 199
goiter, 61
hypercalcemia and, 24
hyperthyroidism, 46, 199
causes, 46
Graves' disease, 48–52
infants born to mothers with, 52–54
hyperemesis gravidarum, 46–48
hypothalamus-pituitary-thyroid axis function, 41–43
fetal thyroid function, 44–45
maternal-placental-fetal interactions, 43–44
TSH receptor antibodies, 45–46
hypothyroidism, 54–57
postpartum thyroid dysfunction, 62, 64–66
single nodule of thyroid gland, 61–62, 63
women on thyroid replacement therapy, 58–59
Thyroidectomy, 681, 682, 804
bone loss from, 324
for follicular thyroid cancer, 777–778
for papillary thyroid carcinoma, 736, 741–742
Thyroid hormone replacement therapy, bone loss from, 374–375, 404–407
Thyroid hormone suppressive therapy, 682–686. See also *Levothyroxine.*
algorithm, 693
appropriate levels, 691–692
bone mineral density effects, 689–691
cardiac function effects, 688–689
diagnostic use, 680
exclusion criteria in controlled trials, 686, 687
levels of serum thyroglobulin while on versus off, 855–856
randomized trials, 683, 685
recent uncontrolled studies, 683, 684
recommendations, 692–693
serum thyroglobulin/TSH relationships and, 856–858
treated versus untreated patients in controlled trials, 683, 686
Thyroiditis, in pregnancy, 59–60
postpartum, 65
Thyroid lobectomy (and isthmusectomy), 682, 741, 777, 804
Thyroid nodules, **663–710**
diagnostic evaluation, 669
algorithm, 681

fine-needle aspiration, adjuncts, 680
distribution of results, 677
impact on clinical practice, 676–677
reliability, 679
specimen adequacy, 677–678
suspicious results, 678–679
history and physical examination, age and gender effects, 669–670
benign thyroid disease history, 671–672
clues on physical examination, 672–673
family history, 671
head and neck irradiation effect, 670
local symptoms, 671
laboratory and radiographic evaluation, miscellaneous radiographic techniques, 676
radionuclide scanning, 674–675
serum testing, 673–674
ultrasonography, 675–676
suppressive therapy, 680
differential diagnosis, 667–668
management, thyroid hormone suppressive therapy, 682–686
algorithm, 693
appropriate levels, 691–692
bone mineral density effects, 689–691
cardiac function effects, 688–689
exclusion criteria in controlled trials, 686, 687
randomized trials, 683, 685
recent uncontrolled studies, 683, 684
recommendations, 692–693
treated versus untreated patients in controlled trials, 683, 686
thyroid surgery, 681–682
prevalence, age and gender effects, 664, 666
chronic disease effect, 667
irradiation effect, 666–667
method of detection and, 664
in unselected population studies, 665
special circumstances, autonomously functioning thyroid nodules, 694
thyroid cysts, 693–694
thyroid nodules in setting of childhood head and neck irradiation, 695
Thyroid-receptor hormone, in pregnancy, 43–44
Thyroid replacement therapy, in pregnancy, 56, 58–59
Thyroid-stimulating hormone (TSH). See also *Thyroid hormone suppressive therapy.*
aging and, 218–219
in bone disease, 374, 375, 405–407
in pregnancy, 2, 42–46, 54–60
radioiodine therapy and, 816–817, 819
serum thyroglobulin levels and, 855–858
TSH receptor in thyroid cancer, 868, 870
Thyroid surgery, 680
for follicular thyroid cancer, 776–778
for papillary thyroid carcinoma, 736
extent of thyroid resection, 741–742
preoperative planning, 740–741
radioiodine therapy and, 804
Thyrotoxicosis, bone disease from, 374–375
follicular thyroid cancer and, 774
neonatal, 53
Thyrotoxic osteopathy, 374
Thyrotropin. See *Thyroid-stimulating hormone.*
Thyrotropin receptor antibody, in pregnancy, 45–46
Thyrotropin-releasing hormone, in pregnancy, 43–44
Thyrotropin-stimulating hormone, in pregnancy, 2, 42–44, 54–60
Thyrotropin-stimulating hormone receptor antibodies, in pregnancy, 45–46
Thyroxine (T4), in pregnancy, 2, 41–44
serum free (FT4), in Graves' disease, 49, 50
Thyroxine-binding globulin, in pregnancy, 41–43
TNF, immunologic response and, 187, 188, 194–195
TNF-α, in follicular thyroid cancer, 792
TNM stgaing of papillary thyroid carcinoma, 737–738
Tobacco. See *Smoking.*
Tolazamide, 260
Tolbutamide, 260
Trabecular variant of papillary thyroid carcinoma, 727–728
Transient hyperthyroidism of hyperemesis gravidarum, 46–48
Transtubular potassium gradient, 584–585
TRH, in pregnancy, 43–44
Triamterene, hyperkalemia and, 581
in primary aldosteronism, 607–608
Triiodothyronine (T3), in pregnancy, 2, 41–44
serum free (FT3), in Graves' disease, 49, 50
TSH. See *Thyroid-stimulating hormone.*
Tumor necrosis factor, immunologic response and, 187, 188, 194–195
Tumor necrosis factor-alpha, in follicular thyroid cancer, 792
Tumor suppressor genes, in follicular thyroid cancer, 872–877
Tyrosine kinase oncogenes, in papillary carcinoma, 870–872

Ultrasonography of thyroid nodules, 675–676

Ultrasound transmission velocity, bone fragility and, 339
Urinary tetrahydro 18-oxocortisol and 18-hydroxycortisol, in primary aldosteronism, 602, 603
Urogenital atrophy, 284–285
Uterine quiescence in pregnancy, relaxin and, 182

Vaginal atrophy, 284–285
Vascular function, magnesium deficiency and, 632–634
Vasoconstrictive drug therapy, in orthostatic edema, 543–546
Vasoconstrictors, in body homeostasis, 460, 462
Vasodilation, in cirrhosis, 465–466
  in pregnancy, 469
Vasodilators, in body homeostasis, 460–461, 462
Vasopressin (AVP), in Alzheimer's disease, 240
  alterations, 241
  blood, 243
  brain, 241
  cerebrospinal fluid, 242
  clinical manifestations of altered secretions, 243–244
  extrahypothalamic, 241–242
  basal plasma levels, 235–236
  in cardiac failure, 468
  in cerebrospinal fluid in normal aging, 235
  changes with normal aging, 239
  in diabetes insipidus, 550–551, 553–565
    in pregnancy, 8
  impaired action, 239–240
  medications and, 244
  in nephrotic syndrome, 472
  neurohypophyseal system and, 234
  stimulation studies, 236–239
  suprachiasmatic nucleus and, 234
Vegetarian diet for hypertension, 652
Vertebral crush fracture syndrome, 349
Vitamin D, anticonvulsants and, 410–411
  metabolism, magnesium deficiency and, 630–631
  in osteomalacia, 381
  in osteoporosis, 331–332
    glucocorticoid-induced, 400, 402
    prevention, 341, 345–346
    treatment, 347, 355
  in pregnancy, 17
    deficiency, hypocalcemia and, 26
  secondary hyperparathyroidism and, 379, 380
Vocal cord paralysis, from radioiodine therapy, 825

Water load test, in orthostatic edema, 541
Water regulation in elderly, 233–243
Water retention and excretion. See also *Edema.*
  renal sodium and, 459–462
Weight at birth, maternal diabetes and, 89–90, 106–108
Weight gain, in orthostatic edema, 539–540, 541
Weight reduction diet for hypertension, 650
White classification, 74
Women, reproductive system of. See *Menopause and aging female reproductive system.*

Zinc, in elderly diabetic patients, 258